Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIS Birch tablets for tree pollen-induced allergic rhinoconjunctivitis
2018-002596-18Phase 3Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Sep 2018
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Birch allergoid in allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Lofarma S.p.A. Primary endpoint: Primary efficacy endpoint. Started Sep 2018; status: completed.
02
Drugs
Birch allergoid
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2018-002596-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002596-18.